Piper Sandler Reiterates Overweight on Bristol-Myers Squibb, Raises Price Target to $82
Piper Sandler analyst David Amsellem reiterates Bristol-Myers Squibb (NYSE:BMY) with a Overweight and raises the price target from $75 to $82.
Share
Why It Matters
A stock expert thinks Bristol-Myers Squibb looks like a good buy. He raised his price guess from $75 to $82 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.